Stroke
Conditions
Interventions
Contralateral controlled functional electrical stimulation combined with mirror therapy group(Part 1):On the basis of routine rehabilitation treatment, participants receive contralateral controlled fu
Mirror therapy group(Part 1):On the basis of routine rehabilitation treatment, participants receive mirror therapy once a day for 20 minutes, 5 days a week, for a total of 3 weeks.
Contralateral control of the functional electrical stimulation group(Part 1):On the basis of routine rehabilitation treatment, participants receive contralateral controlled functional electrical stimu
Lesion-side DLPFC high-frequency rTMS+ contralateral controlled functional electrical stimulation combined with mirror therapy group (Part 2):On the basis of routine rehabilitation treatment, particip
Contralateral DLPFC high-frequency rTMS+ contralateral controlled functional electrical stimulation combined with mirror therapy group(Part 2):On the basis of routine rehabilitation treatment, partici
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Confirmed diagnosis of a first, single unilateral ischemic or hemorrhagic stroke by head computed tomography (CT) or magnetic resonance imaging (MRI); (2) Onset of stroke more than one month; (3) Aged between 18 and 80years; Male or Female; (4) A pretreatment Medical Research Council (MRC) scale of = 26, junior high school and above: MLAST-a + MLAST-b>=27); fairly good cognitive function, as defined by scores on the MMSE>=17/30 points for illiterate participants, >=20/30 points for primary school participants, or >= 24/30 points for secondary school participants; (7) Sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Previous central nervous system diseases; (2) Contraindications for neurophysiological evaluation, electrical stimulation therapy, and near-infrared brain functional imaging include epidermal damage, fever, history of tumors, wearing pacemakers, metal implants or other metal implants in the skull or skull defects, epilepsy patients, pregnant or lactating women, or women of childbearing age who have not taken reliable contraceptive measures; (3) Individuals with severe systemic diseases who are unable to participate in the study: those with comorbidities of the respiratory, heart, liver, kidney, endocrine, and hematopoietic systems, such as congestive heart failure, arrhythmia, and uncontrolled hypertension; (4) Diseases that significantly impair or affect upper limb movement: severe upper limb infections, contractures, joint surgeries, amputations, fractures, rheumatism or rheumatoid arthritis; (5) Individuals with severe cognitive, speech, visual, hearing impairments (such as deaf and mute individuals) or mental disorders that affect examination and treatment; (6) Participation in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Motor function;Dual-site paired pulsed TMS detection index; | — |
Secondary
| Measure | Time frame |
|---|---|
| Embodied ability assessment;Motor Imagination Ability;Task state and resting state fNIRS ;MEP assessment; | — |
Countries
China
Contacts
Public ContactZhang Yuqian
Huashan Hospital, Fudan University
Outcome results
None listed